Respiratory
Pipeline
About our Respiratory Diseases efforts
We are building on a heritage of more than a century in respiratory diseases, with treatments in asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrotic interstitial lung diseases. Our R&D approach leverages our deep understanding and extensive expertise in respiratory medicine, inflammation and fibrosis to develop the next generation of innovative therapies for patients with a broad range of lung diseases who have a high unmet medical need.
Respiratory
Idiopathic pulmonary fibrosis
PDE4B inhibitor
Nerandomilast (BI 1015550)
Respiratory
Progressive pulmonary fibrosis
PDE4B inhibitor
Nerandomilast (BI 1015550)
Respiratory
Non-cystic fibrosis bronchiectasis
CatC inhibitor
BI 1291583
Respiratory
Idiopathic/progressive pulmonary fibrosis
Lysophospholipase inhibitor
BI 1819479